Neuropathic pain: Spotlighting anatomy, experimental models, mechanisms, and therapeutic aspects

Kankowski, Svenja; Grothe, Claudia; Haastert‐Talini, Kirsten

doi:10.1111/ejn.15266

Cited by 17 publications

(8 citation statements)

References 175 publications

(280 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SIP30 is involved in sensory synaptic processing and plays an important role in neuropathic pain [ [8] , [9] , [10] ]. Neuropathic pain, affecting 7 %–15 % of the general population [ [32] , [33] , [34] , [35] ], poses a considerable clinical challenge with unsatisfactory treatment options [ 12 , 15 , 36 , 37 ]. Despite persistent effort to develop drugs for neuropathic pain, the field has encountered a high failure rate [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

“…Neuropathic pain, a pathological condition of the nervous system, has been documented in rodents, domesticated animals, and human, and is commonly studied in both rodent models and human subjects [ [15] , [16] , [17] ]. In this study, we investigated SIP30 messenger RNA sequences in selected species of primates (including human), domesticated animals, and rodents.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Phylogenetic analysis of mammalian SIP30 sequences indicating accelerated adaptation of functional domain in primates

Guo,

Raincrow,

Chiu

et al. 2024

Biochemistry and Biophysics Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Phylogenetic analysis of mammalian SIP30 sequences indicating accelerated adaptation of functional domain in primates

Guo,

Raincrow,

Chiu

et al. 2024

Biochemistry and Biophysics Reports

View full text Add to dashboard Cite

“…The mechanism of neuropathic pain in peripheral and central nervous systems is complex, and key interactions within sensory pathways have been discovered, but no common molecular mechanism leading to neuropathic pain has been identified [48,49]. An overview of the pathophysiology of trigeminal PTNP has recently been published [50].…”

Section: Discussionmentioning

confidence: 99%

Onabotulinum toxin a treatment for posttraumatic trigeminal neuropathic pain: case series and literature review

2024

Journal of Oral &Amp; Facial Pain and Headache

View full text Add to dashboard Cite

This case series aimed to assess the treatment outcomes of onabotulinum toxin A (BTX-A) in patients with refractory posttraumatic trigeminal neuropathic pain (PTNP) and to conduct a narrative review of the evidence for BTX-A in PTNP. Thirteen patients were treated with BTX-A infiltrations. Patient demographic and pain characteristics, BTX-A administration, and treatment outcomes were retrospectively analyzed. Papers retrieved after a literature search of articles on PTNP treatment using BTX-A were reviewed. Six patients reported an improvement in pain 3 months after the initial BTX-A injection, with 4 patients reporting a 50% reduction. Two patients achieved an 80% reduction in pain score over 3 years of BTX-A therapy. Three patients reported temporary ipsilateral facial muscle weakness. The literature review revealed five case reports on the use of BTX-A in PTNP patients that reported similar effectiveness to the present cohort study. BTX-A may be a potential treatment modality for refractory PTNP, thus reducing the need for polypharmacy. Multiple intraoral BTX-A injections administered over the painful sites are well tolerated, safe and easily practiced. High-quality studies are required to evaluate the long-term therapeutic efficacy and side effects of BTX-A therapy.

show abstract

“…Unlike physiological pain, however, neuropathic pain (NP) does not originate from the stimulation of distal nerve endings but is a secondary consequence of injury or disease of the nervous system (Kankowski et al. 2021 ). NP is often caused by the remodeling of nociceptors due to lesions in the peripheral or central nervous system, which triggers pain sensitization in the body (Li et al.…”

Section: Introductionmentioning

confidence: 99%

Daphnetin alleviates neuropathic pain in chronic constrictive injury rats via regulating the NF-κB dependent CXCL1/CXCR2 signaling pathway

Zhang

Liang

et al. 2023

Pharmaceutical Biology

View full text Add to dashboard Cite

Context Daphnetin is a natural product with anti-inflammatory, antioxidant, and neuroprotective properties. Reports have found that it has a strong analgesic effect; however, its analgesic mechanism is unknown. Objective We explored the effect and mechanism of daphnetin on neuropathic pain (NP). Materials and methods The rat model of NP was established by ligation of the sciatic nerve. Male Sprague-Dawley rats were divided into six groups: Control, Model, Sham, morphine (0.375 mg/kg), and daphnetin (0.0625 and 0.025 mg/kg). Rats were intrathecally injected with drugs or normal saline once daily for three days. Hyperalgesia was evaluated by mechanical withdrawal threshold (MWT) and thermal withdrawal threshold (TWT). Protein levels were detected using ELISA, immunofluorescence, and western blotting. Results Compared to the Model group, daphnetin improved TWT (46.70 °C vs. 42.20 °C) and MWT (45.60 g vs. 23.60 g), reduced the expression of interleukin-1β (0.99 ng/g vs. 1.42 ng/g), interleukin-6 (0.90 ng/g vs. 1.52 ng/g), and tumor necrosis factor-α (0.93 ng/g vs. 1.52 ng/g) in the sciatic nerve. Daphnetin decreased the expression of toll-like receptor 4 (TLR4) (0.47-fold), phosphorylated inhibitor of NF-κB (p-IKBα) (0.29-fold), nuclear factor kappaB (NF-κB) (0.48-fold), glial fibrillary acidic protein (GFAP) (0.42-fold), CXC chemokine ligand type 1 (CXCL1) (0.84-fold), CXC chemokine receptor type 2 (CXCR2) (0.78-fold) in the spinal cord. Discussion and conclusions Daphnetin alleviates NP by inhibiting inflammation and astrocyte activation in the spinal cord, providing theoretical support for the extensive clinical treatment of NP.

show abstract

Neuropathic pain: Spotlighting anatomy, experimental models, mechanisms, and therapeutic aspects

Cited by 17 publications

References 175 publications

Phylogenetic analysis of mammalian SIP30 sequences indicating accelerated adaptation of functional domain in primates

Phylogenetic analysis of mammalian SIP30 sequences indicating accelerated adaptation of functional domain in primates

Onabotulinum toxin a treatment for posttraumatic trigeminal neuropathic pain: case series and literature review

Daphnetin alleviates neuropathic pain in chronic constrictive injury rats via regulating the NF-κB dependent CXCL1/CXCR2 signaling pathway

Contact Info

Product

Resources

About